Neurocrine Biosciences
NBIX
$115.16
Share price
-0.26%
Change (1 day)
22.43%
Change (1 year)
Categories
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.
Neurocrine Biosciences (NBIX) - Total liabilities
Total liabilities on the balance sheet as of June 2023 : $0.76 B
According to Neurocrine Biosciences 's latest financial reports the company's total liabilities are $0.76 B. A company’s total liabilities is the sum of all current and non-current debts and obligations.
Neurocrine Biosciences - Total liabilities on balance sheet (from 2001 to 2023)
Total liabilities by year
| Year | Total liabilities | Change |
|---|---|---|
| 2022-12-31 | $0.66 B | -5.38% |
| 2021-12-31 | $0.69 B | 14.79% |
| 2020-12-31 | $0.60 B | -9.06% |
| 2019-12-31 | $0.66 B | 30.59% |
| 2018-12-31 | $0.51 B | 15.03% |
| 2017-12-31 | $0.44 B | 787.2% |
| 2016-12-31 | $50.2 M | -0.24% |
| 2015-12-31 | $50.33 M | 46.59% |
| 2014-12-31 | $34.33 M | 0.2% |
| 2013-12-31 | $34.26 M | -17.64% |
| 2012-12-31 | $41.6 M | -46.85% |
| 2011-12-31 | $78.28 M | -37.41% |
| 2010-12-31 | $0.12 B | 87.06% |
| 2009-12-31 | $66.86 M | -17.87% |
| 2008-12-31 | $81.4 M | -48.46% |
| 2007-12-31 | $0.15 B | 110.72% |
| 2006-12-31 | $74.96 M | -19.41% |
| 2005-12-31 | $93.01 M | -25.82% |
| 2004-12-31 | $0.12 B | -23.47% |
| 2003-12-31 | $0.16 B | 287.45% |
| 2002-12-31 | $42.28 M | 17.6% |
| 2001-12-31 | $35.95 M |
Total liabilities for similar companies or competitors
| Company | Total liabilities | differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | $94.38 B | 12,316.92% | 🇺🇸 USA |
 AbbVie ABBV | $121.24 B | 15,850.66% | 🇺🇸 USA |
 Eli Lilly LLY | $43.66 B | 5,644.60% | 🇺🇸 USA |
 Repligen
RGEN | $0.57 B | -23.95% | 🇺🇸 USA |
 Athersys ATHX | $47.89 M | -93.70% | 🇺🇸 USA |
 ANI Pharmaceuticals ANIP | $0.42 B | -44.10% | 🇺🇸 USA |
 Palatin Technologies PTN | $16.01 M | -97.89% | 🇺🇸 USA |
 Royalty Pharma RPRX | $7.30 B | 861.43% | 🇬🇧 UK |